Clinical Trial Update: A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating CHT102 for MSLN-positive advanced pancreatic cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• CHT102

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Advanced Pancreatic Cancers | Phase 1 | Status: RECRUITING